Vertex's zimislecel program shows promising clinical findings at ADA conference.

From Yahoo Finance: 2025-06-29 12:53:00

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) is considered one of the best fundamental stocks to buy by hedge funds, with a price target of $550 and a Buy rating from H.C. Wainwright. Updated data from the zimislecel program was featured at the American Diabetes Association conference.

Clinical findings showed that 83% of patients in Vertex’s zimislecel program became insulin independent, achieving primary composite endpoints with sustained C-peptide restoration. This demonstrates the treatment’s potential efficacy in improving patient outcomes.

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) aims to expand its therapeutic areas beyond cystic fibrosis therapies with the zimislecel program. The company is known for its involvement in the discovery and development of small-molecule medications for severe illnesses.

While VRTX presents investment potential, some AI stocks may offer greater upside and less downside risk. Investors seeking undervalued AI stocks can explore opportunities that benefit from Trump-era tariffs and the onshoring trend.

For more information on top-performing stocks, including Magic Formula and retirement stocks, visit the provided links. Disclosure: None.



Read more at Yahoo Finance: H.C. Wainwright Reaffirms Vertex Buy Rating After ADA Conference Results